Mucopolysaccharidosis VI
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Mucopolysaccharidosis VI, or MPS VI, is an inherited lysosomal storage disease caused by deficient activity of the enzyme arylsulfatase B. Without normal enzyme function, glycosaminoglycans accumulate within cells and tissues, producing progressive skeletal, eye and connective-tissue abnormalities.
The disorder has been described in Siamese and related cats. Affected kittens may develop a broad face, reduced growth, joint stiffness, abnormal gait, chest deformity and changes in the spine. Corneal clouding can impair vision. The skeleton becomes progressively abnormal because storage interferes with normal cartilage and bone development.
Unlike primarily neurological gangliosidoses, MPS VI often produces striking musculoskeletal disease. Cats can remain mentally alert while mobility becomes increasingly limited. Heart, airway or other organ involvement may occur depending on severity.
Recognised feline MPS VI is inherited as an autosomal recessive trait. Carriers have normal appearance and function. There is no widely available routine therapy that corrects enzyme deficiency throughout the body once disease is established. Supportive care can improve comfort but does not stop storage from progressing. The condition is therefore an important target for carrier screening in affected breeding lines, where prevention is far more effective than treatment of severely affected kittens.
The storage material accumulates in cartilage, bone and connective tissues throughout the body, so the cat may appear to have several unrelated orthopaedic problems at once. Recognising the systemic pattern prevents repeated treatment of individual joints without identifying the inherited metabolic disease linking them together.
Because the disorder is systemic, apparent changes in gait, vision and body shape should be interpreted together. A kitten with progressive stiffness and corneal clouding is more suggestive of a storage disease than one with a single isolated joint abnormality.
Genetic results are especially useful before breeding because carriers have no clinical signs.
Screening & Early Detection
Young cats with progressive joint stiffness, unusual facial structure, corneal clouding or multiple skeletal abnormalities should be investigated for a storage disease when breed and family history fit. Radiographs can reveal characteristic changes but do not identify the specific enzyme defect.
Enzyme testing for arylsulfatase B activity provides a biochemical diagnosis. Validated DNA tests can identify normal, carrier and affected genotypes in recognised lines where the causative variant is known.
Eye examination documents corneal involvement, while cardiac and respiratory assessment may be appropriate in more severely affected cats. The veterinarian also evaluates mobility and pain because secondary joint degeneration can add discomfort to the structural disease.
Routine screening is targeted to at-risk breeds and families rather than the general cat population. Early identification of carriers prevents affected litters, while early diagnosis in a symptomatic kitten allows realistic planning and avoids repeated treatment for isolated joint problems that are actually part of a systemic storage disorder.
Diagnosis can be confirmed by measuring arylsulfatase B activity or by breed-specific genetic testing where a validated mutation is available. Radiographs can document characteristic skeletal changes, and ophthalmic examination assesses corneal involvement.
Treatment & Management
There is no standard treatment that replaces missing arylsulfatase B throughout all affected tissues. Management therefore focuses on comfort and function. Pain from secondary joint disease is treated appropriately, and the home is adapted with non-slip flooring, ramps, low-entry litter trays and easy access to resources.
Body weight should remain lean because extra weight places additional load on abnormal joints and spine. Physiotherapy may help maintain comfortable range of motion but should not force structurally abnormal joints. Corneal disease is monitored and treated for comfort when secondary inflammation occurs.
Severe skeletal or airway abnormalities may limit what can be achieved medically. Surgical correction is considered only for specific problems where a clear functional benefit is expected. Experimental enzyme or gene therapies are not routine clinical options for pet cats.
The long-term prognosis depends on severity but is guarded because structural changes progress. Breeding prevention through enzyme or DNA testing is central. Carrier cats are healthy and do not require treatment, but mating plans should ensure they are not paired in a way that can produce affected kittens.
Regular nail and skin care can become important when abnormal joints limit self-grooming or alter the way the cat bears weight on the feet.
Breeds or species affected
Colorpoint Shorthair
Open cat breed description, care requirements and conditions
Oriental Longhair
Open cat breed description, care requirements and conditions
Oriental Shorthair
Open cat breed description, care requirements and conditions
Siamese
Open cat breed description, care requirements and conditions
Thai
Open cat breed description, care requirements and conditions